Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
1.530
0.00 (0.00%)
At close: Mar 9, 2026, 4:00 PM EDT
1.550
+0.020 (1.31%)
After-hours: Mar 9, 2026, 5:38 PM EDT
Daré Bioscience Revenue
Daré Bioscience had revenue of $2.26K in the quarter ending September 30, 2025, a decrease of -94.57%. This brings the company's revenue in the last twelve months to $-57.13K, down -103.04% year-over-year. In the year 2024, Daré Bioscience had annual revenue of $9.78K, down -99.65%.
Revenue (ttm)
$-57.13K
Revenue Growth
-103.04%
P/S Ratio
-382.69
Revenue / Employee
n/a
Employees
23
Market Cap
21.86M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionDARE News
- 14 days ago - Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - GlobeNewsWire
- 3 months ago - DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility - GlobeNewsWire
- 3 months ago - Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript - Seeking Alpha
- 4 months ago - Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025 - GlobeNewsWire
- 5 months ago - Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research - GlobeNewsWire
- 7 months ago - Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript - Seeking Alpha